Harold Simmons Center for Kidney Disease Research and Epidemiology, Division of Nephrology and Hypertension, University of California Irvine, School of Medicine, Orange, CA, USA.
Nephrol Dial Transplant. 2013 Aug;28(8):2146-55. doi: 10.1093/ndt/gft213. Epub 2013 Jun 5.
In hemodialysis patients, higher serum creatinine (Cr) concentration represents larger muscle mass and predicts greater survival. However, this association remains uncertain in peritoneal dialysis (PD) patients.
In a cohort of 10 896 PD patients enrolled from 1 July 2001 to 30 June 2006, the association of baseline serum Cr level and change during the first 3 months after enrollment with all-cause mortality was examined.
The cohort mean ± SD age was 55 ± 15 years old and included 52% women, 24% African-Americans and 48% diabetics. Compared with patients with serum Cr levels of 8.0-9.9 mg/dL, patients with serum Cr levels of <4.0 mg/dL and 4.0-5.9 mg/dL had higher risks of death {HR 1.36 [95% confidence interval (95% CI) 1.19-1.55] and 1.19 (1.08-1.31), respectively} whereas patients with serum Cr levels of 10.0-11.9 mg/dL, 12.0-13.9 mg/dL and ≥14.0 mg/dL had lower risks of death (HR 0.88 [95% CI 0.79-0.97], 0.71 [0.62-0.81] and 0.64 [0.55-0.75], respectively) in the fully adjusted model. Decrease in serum Cr level over 1.0 mg/dL during the 3 months predicted an increased risk of death additionally. The serum Cr-mortality association was robust in patients with PD treatment duration of ≥12 months, but was not observed in those with PD duration of <3 months.
Muscle mass reflected in serum Cr level may be associated with survival even in PD patients. However, the serum Cr-mortality association is attenuated in the early period of PD treatment, suggesting competing effect of muscle mass versus residual renal function on mortality.
在血液透析患者中,较高的血清肌酐(Cr)浓度代表更大的肌肉量,并预测更高的生存率。然而,这种关联在腹膜透析(PD)患者中仍然不确定。
在 2001 年 7 月 1 日至 2006 年 6 月 30 日期间纳入的 10896 名 PD 患者队列中,研究了基线血清 Cr 水平和入组后前 3 个月内的变化与全因死亡率之间的关系。
该队列的平均年龄为 55 ± 15 岁,包括 52%的女性、24%的非裔美国人以及 48%的糖尿病患者。与血清 Cr 水平为 8.0-9.9mg/dL 的患者相比,血清 Cr 水平<4.0mg/dL 和 4.0-5.9mg/dL 的患者死亡风险更高{风险比(HR)为 1.36(95%置信区间(95%CI)为 1.19-1.55)和 1.19(1.08-1.31)},而血清 Cr 水平为 10.0-11.9mg/dL、12.0-13.9mg/dL 和≥14.0mg/dL 的患者死亡风险较低(HR 分别为 0.88(95%CI 为 0.79-0.97)、0.71(0.62-0.81)和 0.64(0.55-0.75)),在完全调整后的模型中。在 3 个月内血清 Cr 水平下降超过 1.0mg/dL 也预示着死亡风险增加。该血清 Cr-死亡率的关联在 PD 治疗时间≥12 个月的患者中是稳健的,但在 PD 治疗时间<3 个月的患者中则没有观察到。
血清 Cr 水平反映的肌肉量可能与 PD 患者的生存有关。然而,在 PD 治疗的早期阶段,血清 Cr 与死亡率的关联减弱,这表明肌肉量与残余肾功能对死亡率的竞争效应。